PMID- 23688207
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20191112
IS  - 2212-3970 (Electronic)
IS  - 1574-8928 (Linking)
VI  - 8
IP  - 3
DP  - 2013 Sep
TI  - Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen 
      receptors.
PG  - 239-54
AB  - Solid tumors contain several different types of malignant cells. This cellular 
      heterogeneity complicates therapy for at least two reasons. First, each 
      subpopulation may respond differently to a given treatment. Second, cancer cells 
      are plastic, and thus may convert from a therapy-sensitive to a therapy-resistant 
      cell type represented by another subpopulation. Therefore, successful therapies 
      will have to target numerous malignant cell types, not just the rapidly 
      proliferating cells as most standard treatments do. Immunotherapies with T cells 
      engineered to recognize cancer cells via bispecific antibodies (bsAbs) or 
      chimeric antigen receptors (CARs) are particularly promising approaches with 
      potential to ablate both dividing and non/slow-dividing subpopulations of cancer 
      cells. Here, we discuss several patents associated with exceptionally effective 
      bsAbs of the tandem single-chain variable fragment (taFv) class and untangle a 
      part of the complex network of patents directly or indirectly related to CARs. 
      Furthermore, we speculate on the future of bsAbs and CARs for both treatment and 
      prevention of solid tumors such as prostate cancer.
FAU - Lacher, Markus D
AU  - Lacher MD
AD  - T cell Therapeutics, Inc., Lafayette, 94549 CA, USA. doublehelix.pb2k@gmail.com
FAU - Provenzano, Maurizio
AU  - Provenzano M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Anticancer Drug Discov
JT  - Recent patents on anti-cancer drug discovery
JID - 101266081
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Animals
MH  - Antibodies, Bispecific/*biosynthesis/genetics
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/genetics/immunology/pathology/*therapy
MH  - Patents as Topic
MH  - Receptors, Antigen, T-Cell/*biosynthesis/genetics
MH  - Recombinant Fusion Proteins/*biosynthesis/genetics
MH  - T-Lymphocytes/*immunology
EDAT- 2013/05/22 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/03/08 00:00 [received]
PHST- 2013/05/09 00:00 [revised]
PHST- 2013/05/09 00:00 [accepted]
PHST- 2013/05/22 06:00 [entrez]
PHST- 2013/05/22 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - PRA-EPUB-20130513-1 [pii]
AID - 10.2174/15748928113088880003 [doi]
PST - ppublish
SO  - Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):239-54. doi: 
      10.2174/15748928113088880003.